Inpharma 1374 - 15 Feb 2003

■ The rebeccamycin analogue XL 119* showsantitumour activity in hepatobiliary tumours,according to preliminary data presented recently at the14th International Congress on Anti-Cancer Treatment,held in Paris, France. In this phase II study, 20 patientswith advanced unresectable bile duct cancers receivedIV infusions of XL 119 165 mg/m2/day for 5 days every3 weeks. After a median follow-up of 12.5 months,nine patients were still alive. Partial responses wereachieved by two patients and disease stabilisation byanother seven. Adverse events included transient,reversible myelosuppression, primarily neutropenia.* Exelixis Pharmaceuticals, Bristol-Myers Squibb; phase II

Exelixis Inc. Exelixis Announces Presentation of Preliminary Phase 2 Data onRebeccamycin Analogue in Hepatobiliary Tumors. Media Release : 3 Feb2003. Available from: URL: http://www.exelixis.com 809017880

1

Inpharma 15 Feb 2003 No. 13741173-8324/10/1374-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved